{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:35:45Z","timestamp":1770507345147,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,1,29]],"date-time":"2015-01-29T00:00:00Z","timestamp":1422489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00280-015-2687-x","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T11:29:40Z","timestamp":1422444580000},"page":"711-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Hyeong Su","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Young","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Suk","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang Yong","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Woong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choong Kee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Hyeok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Il","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boram","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hunho","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hye","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Ro","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Young","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,29]]},"reference":[{"key":"2687_CR1","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","volume":"341","author":"PC Groen de","year":"1999","unstructured":"de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341:1368\u20131378. doi: 10.1056\/NEJM199910283411807","journal-title":"N Engl J Med"},{"key":"2687_CR2","first-page":"415","volume":"159","author":"D Oertli","year":"1993","unstructured":"Oertli D, Herzog U, Tondelli P (1993) Primary carcinoma of the gallbladder: operative experience during a 16\u00a0year period. Eur J Surg 159:415\u2013420","journal-title":"Eur J Surg"},{"key":"2687_CR3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sj\u00f6d\u00e9n PO, Jacobsson G, Sellstr\u00f6m H, Enander LK, Linn\u00e9 T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593\u2013600","journal-title":"Ann Oncol"},{"key":"2687_CR4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1634\/theoncologist.2007-0252","volume":"13","author":"AF Hezel","year":"2008","unstructured":"Hezel AF, Zhu AX (2008) Systemic therapy for biliary tract cancers. Oncologist 13:415\u2013423. doi: 10.1634\/theoncologist.2007-0252","journal-title":"Oncologist"},{"key":"2687_CR5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281. doi: 10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"2687_CR6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548\u2013557","journal-title":"Anticancer Drugs"},{"key":"2687_CR7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/sj.bjc.6602208","volume":"91","author":"H Ueno","year":"2004","unstructured":"Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91:1769\u20131774. doi: 10.1038\/sj.bjc.6602208","journal-title":"Br J Cancer"},{"key":"2687_CR8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","volume":"62","author":"J Furuse","year":"2008","unstructured":"Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849\u2013855. doi: 10.1007\/s00280-007-0673-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"2687_CR9","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00280-009-1115-5","volume":"65","author":"T Sasaki","year":"2010","unstructured":"Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M (2010) Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65:1101\u20131107. doi: 10.1007\/s00280-009-1115-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"2687_CR10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00280-010-1443-5","volume":"67","author":"M Kanai","year":"2011","unstructured":"Kanai M, Yoshimura K, Tsumura T, Asada M, Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K, Taura K, Mori Y, Hamada A, Inoue N, Tada S, Yanagihara K, Yazumi S, Osaki Y, Chiba T, Ikai I, Fukushima M, Uemoto S, Hatano E (2011) A multi-institution phase II study of gemcitabine\/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 67:1429\u20131434. doi: 10.1007\/s00280-010-1443-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"2687_CR11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00280-013-2090-4","volume":"71","author":"T Sasaki","year":"2013","unstructured":"Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Kogure H, Hanada K, Maguchi H, Sasahira N, Kamada H, Mukai T, Okabe Y, Hasebe O, Maetani I, Koike K (2013) A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol 71:973\u2013979. doi: 10.1007\/s00280-013-2090-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"2687_CR12","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/cas.12218","volume":"104","author":"C Morizane","year":"2013","unstructured":"Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, Hamamoto Y, Ishii H, Boku N, Furuse J (2013) Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan clinical oncology group trial (JCOG 0805). Cancer Sci 104:1211\u20131216. doi: 10.1111\/cas.12218","journal-title":"Cancer Sci"},{"key":"2687_CR13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216. doi: 10.1093\/jnci\/92.3.205","journal-title":"J Natl Cancer Inst"},{"key":"2687_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310. doi: 10.1016\/0197-2456(89)90015-9","journal-title":"Control Clin Trials"},{"key":"2687_CR15","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","volume":"23","author":"JJ Knox","year":"2005","unstructured":"Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332\u20132338. doi: 10.1200\/JCO.2005.51.008","journal-title":"J Clin Oncol"},{"key":"2687_CR16","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/cncr.21591","volume":"104","author":"JY Cho","year":"2005","unstructured":"Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced\/metastatic biliary tract carcinoma. Cancer 104:2753\u20132758. doi: 10.1002\/cncr.21591","journal-title":"Cancer"},{"key":"2687_CR17","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/cncr.22902","volume":"110","author":"RP Riechelmann","year":"2007","unstructured":"Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ (2007) Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110:1307\u20131312. doi: 10.1002\/cncr.22902","journal-title":"Cancer"},{"key":"2687_CR18","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00280-011-1657-1","volume":"68","author":"S Iqbal","year":"2011","unstructured":"Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD (2011) A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: southwest oncology group study S0202. Cancer Chemother Pharmacol 68:1595\u20131602. doi: 10.1007\/s00280-011-1657-1","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2687-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2687-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2687-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:11:45Z","timestamp":1559038305000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2687-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,29]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2687"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2687-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,29]]}}}